Abstract
No abstract available
Keywords
Funding Information
  • National Institutes of Health (R01 HD083040-02S1)
  • National Institutes of Health (R01 AI094586)
  • National Institutes of Health (TMA2020CDF-3192-VaViBa)
  • National Institutes of Health (INV-037612)
  • National Institutes of Health (17/43)
  • National Institutes of Health (R01 HD083040-02S1)
  • National Institutes of Health (R01 AI094586)
  • National Institutes of Health (TMA2020CDF-3192-VaViBa)
  • National Institutes of Health (INV-037612)
  • National Institutes of Health (17/43)
  • European and Developing Countries Clinical Trials Partnership (R01 HD083040-02S1)
  • European and Developing Countries Clinical Trials Partnership (R01 AI094586)
  • European and Developing Countries Clinical Trials Partnership (TMA2020CDF-3192-VaViBa)
  • European and Developing Countries Clinical Trials Partnership (INV-037612)
  • European and Developing Countries Clinical Trials Partnership (17/43)
  • Bill and Melinda Gates Foundation (R01 HD083040-02S1)
  • Bill and Melinda Gates Foundation (R01 AI094586)
  • Bill and Melinda Gates Foundation (TMA2020CDF-3192-VaViBa)
  • Bill and Melinda Gates Foundation (INV-037612)
  • Bill and Melinda Gates Foundation (17/43)
  • Poliomyelitis Research Foundation (R01 HD083040-02S1)
  • Poliomyelitis Research Foundation (R01 AI094586)
  • Poliomyelitis Research Foundation (TMA2020CDF-3192-VaViBa)
  • Poliomyelitis Research Foundation (INV-037612)
  • Poliomyelitis Research Foundation (17/43)